455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 137
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Howard W. Robin | CEO, President & Director | 2,21M | S.O. | 1953 |
Ms. Sandra A. Gardiner | Interim Chief Financial Officer | 376,3k | S.O. | 1966 |
Mr. Mark A. Wilson | Senior VP, Chief Legal Officer & Secretary | 868,68k | S.O. | 1972 |
Dr. Jonathan Zalevsky Ph.D. | Chief Research & Development Officer | 1,6M | S.O. | 1975 |
Vivian Wu | Director of Investor Relations & Corporate Affairs | S.O. | S.O. | S.O. |
Mr. Robert Bacci | Senior Vice President of Human Resources & Facilities Operations | S.O. | S.O. | S.O. |
Ms. Jennifer Ruddock | Chief Business Officer | S.O. | S.O. | S.O. |
Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | S.O. | S.O. | 1966 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
L’ISS Governance QualityScore de Nektar Therapeutics en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 8; Société : 7; Droits des actionnaires : 2; Compensation : 8.